Gsa Capital Partners LLP Athira Pharma, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 296,556 shares of ATHA stock, worth $109,725. This represents 0.01% of its overall portfolio holdings.
Number of Shares
296,556
Previous 397,111
25.32%
Holding current value
$109,725
Previous $177,000
1.69%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding ATHA
# of Institutions
62Shares Held
18.8MCall Options Held
17.2KPut Options Held
800-
Perceptive Advisors LLC New York, NY5.4MShares$2 Million0.11% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.78MShares$1.03 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.56MShares$575,9600.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$552,3330.05% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$552,3330.87% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $14M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...